Marcie A. Goldstein

Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the underwriter in connection with the initial public offering of 30,000,000 units of Sustainable Opportunities Acquisition Corp. for aggregate proceeds of $300…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 36,000,000 units of CC Neuberger Principal Holdings I, including 5,400…

Davis Polk advised the representatives of the several underwriters in connection with a $587 million SEC-registered offering of 17,250,000 shares of common stock of Grocery Outlet…

Davis Polk advised the underwriters in connection with the $645 million public offering of 12,835,245 shares of Class A common stock of Tradeweb Markets Inc., which included 1,674,162…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…